Condition: Aortic Dissection · Systemic Inflammatory Response Syndrome · Cardiovascular Diseases (CVD) · Sponsor: Nanjing Medical University
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.
This description comes directly from the study's public registry record.
Hong Liu, MD · +8618801281613 · dr.hongliu@foxmail.com
Sheng Zhao, MD · 02568303105 · zhaosheng0824@163.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital | Beijing, China | Recruiting |
| The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan | Nanjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06195267